The Wall Street Journal, September 29, 2014. The majority of moderate to high-risk medical devices approved by the U.S. Food and Drug Administration lack publicly available scientific evidence to verify their safety and effectiveness despite requirements in the law, according to a study released Monday.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Can the War on Cancer Be Won? A Surprising Answer
Huffington Post, September 16, 2014. Better communication about treatment options will help millions of people avoid ever developing cancer, and also prevent unnecessarily radical and harmful treatments for those who are diagnosed with cancer.
Read More »FDA is Chastised Over its ‘Action Plan’ to Diversify Clinical Trial Participation
The Wall Street Journal, August 28, 2014: NCHR explains to WSJ that the FDA Diversity Action Plans lacks incentives for companies to study their medical products in a diverse group of patients, including sex, age, and race/ethnicity. The FDA urges diversity but approves drugs and implants that have only been evaluated on mostly white patients under 65.
Read More »Surgery Studies Rarely Use Females
The Scientist, August 28, 2014: The Scientist article on lack of women in clinical trials quotes NCHR telling MedPage Today that FDA must increase incentives for companies to include more women, older patients, and people of color in clinical trials. The FDA urges diversity but approves drugs and implants that have not been evaluated on all the types of patients who will want to use the product.
Read More »Ebola Outbreak: A Teachable Moment for Scientists
AAAS, August 2014. The media frenzy surrounding the Ebola crisis in West Africa shows that many journalists don’t understand that an experimental drug is just that – a scientific experiment. It is not a “breakthrough” drug or a “cutting-edge treatment” or a prize to be envied, unless or until it is proven to be safer and more effective than nothing.
Read More »